Gennao Bio Appoints Chris Duke as Chief Operating Officer and Julie Hambleton, M.D., to Board of Directors HOPEWELL, N.J., July 13, 2021 (GLOBE NEWSWIRE) -- Gennao Bio, a privately held genetic medicines company developing first-in-class, targeted nucleic acid therapeutics, today announced the...

Gennao Bio Closes $40 Million Series A Financing to Develop Pipeline of Targeted Nucleic Acid Therapeutics ~ Financing Co-led by OrbiMed and Logos Capital to Support Advancement of Proprietary Gene Monoclonal Antibody Platform (GMAB) ~ ~ Stephen Squinto, Ph.D., Appointed Chief Executive Officer and...

Gennao Bio Presents New Data on Novel Gene Monoclonal Antibody Platform Technology at the American Association for Cancer Research (AACR) 2021 Annual Meeting ~ Preclinical data show the utility of Gennao’s proprietary first-in-class monoclonal antibody 3E10-D31N (GMABD31N), a cell penetrating antibody, to non-covalently bind to and systemically deliver...

Gennao Bio Announces Abstract Accepted for Late-Breaker Poster Presentation at the American Association for Cancer Research (AACR) 2021 Annual Meeting ~ Presentation to highlight the potential of Gennao’s proprietary, non-viral gene monoclonal antibody (GMAB) platform technology to systemically deliver immunostimulatory RNAs to tumors and suppress...